Intellia Therapeutics (NTLA)
(Delayed Data from NSDQ)
$22.52 USD
-0.03 (-0.13%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $22.51 -0.01 (-0.04%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Price, Consensus and EPS Surprise
NTLA 22.52 -0.03(-0.13%)
Will NTLA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for NTLA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NTLA
Intellia's (NTLA) Q2 Earnings & Revenues Fall Shy of Estimates
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Lags Revenue Estimates
NTLA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Intellia (NTLA) to Report Q2 Earnings: What's in the Cards?
Beat the Market Like Zacks: Karooooo, UnitedHealth, Amgen in Focus
Kyverna (KYTX) Gets RMAT Designation for CAR T-Cell Product
Other News for NTLA
Intellia Therapeutics: A Bullish Outlook on Gene Editing Innovation and Market Potential
Intellia Therapeutics initiated with bullish view at JonesResearch, here's why
Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific Meeting
Beam Therapeutics price target raised to $69 from $66 at Stifel
Krystal Biotech price target raised to $220 from $204 at Stifel